Takeda’s non-small cell lung cancer (NSCLC) treatment Mobocertinib (TAK-788) is leading closer to regulatory approval after the U.S. Food and Drug Administration granted priority review to the New Drug Application. 

Takeda Pharmaceutical is advancing the Japanese pharma giant’s immune-oncology portfolio through the acquisition of the immunotherapy pioneer Maverick Therapeutics.

Takeda Pharmaceutical Co. agreed to sell four diabetes products in Japan to Teijin Pharma Ltd. for 133 billion yen ($1.25 billion).


The U.S. Food and Drug Administration approved Takeda Pharmaceutical’s supplemental New Drug Application for Iclusig (ponatinib) for adult patients with chronic-phase chronic myeloid leukemia with resistance or intolerance to at least two prior kinase inhibitors.